The response of serum prolactin (PRL) to thyrotropin-releasing hormone (TRH) was evaluated by radioimmunoassay in 6 normal women and44breast cancer cases. They were divided into the following 5 groups: group 1:6normal women; group 2:10preoperative patients with early breast cancer; group 3: 13 preoperative patients with advanced cancer; group 4: 13 postoperative patients with no recurrence of cancer for more than 2 years; group 5: 8 postoperative patients with cancer recurrence.
The relationship between pituitary gland function and breast cancer has been recognized since first suggested by Gomez and Turner (1937) . There have now been numerous studies (MacMahon et al., 1973; Minton, 1974; Smithline et al., 1975; Hill et al., 1976; Kirschner, 1977; Nagasawa, 1978) on the role of prolactin (PRL) in human breast cancer. Some investigators (Murray, 1972; Rolandi et al., 1974) have found that the blood PRL levels in breast cancer patients are higher than the levels in normal subjects, but others (Boyns et al., 1973; Sheth et at., 1975) have found no significant increase in PRL levels in their patients.
There have also been several receptors on the kinetics of PRL, including its response to thyrotropin releasing hormone (TRH) in patients with breast cancer, (Mittra et al., 1974; Ohgo et al., 1976; Endo et al., 1977; Higuchi et al., 1977) but none state unequivocal findings. Na studies have yet clearly elucidated the relation between PRL response to TRH and recurrence of breast cancer.
In this study a comparison was made between patients with and without recurrence of breast cancer with respect to PRL response to TRH. dition, sera of all cases were assayed (Masuoka and Mimoto, 1978) for detection of human thyroglobulin antibody (Sorin, Saluggia, Italy).
To investigate the degree of response of serum PRL and TSH to TRH we calculated the mean maximum increment above the basal level (max JPRL and max JTSH) by measuring peak PRL or TSH value after administration of TRH minus basal PRL or TSH value.
Statistical analysis of PRL and TSH values between these groups was performed by the Student's t-test and linear regression analysis was done by the method of least squares.
Results

Prolactin
No significant differences were observed between any two groups in the basal level of serum PRL. Fig.1shows the time course of the serum PRL levels after administration of TRH.
In all groups the PRL value reached its peak after15or 30minutes
following TRH injection and declined gradually thereafter. Thyroid-stimulating hormone There were no significant differences in the mean response to TRH between the 5different groups and no correlations were observed between the basal levels of TSH and PRL or in their response to TRH.
Thyroglobulin antibody We detected circulating thyroglobulin antibody in4postoperative patients without recurrence (group 4) but none in any patients from other groups. All PRL values of these4patients
were approximate to the mean value of the group. Their TSH values were higher than those of other patients but not statistically significant.
Discussion
As Welsch and Nagasawa (1977) detailed, in recent years, a large body of experimental data has been accumulated demonstrating a key role for PRL in the development and growth of murine mammary tumors. Although there have been some reports that the blood PRL concentrations of breast cancer patients are higher than those of normal subjects (Murray et al., 1972; Rolandi et al., 1974) , most studies to date have found the blood PRL concentrations to be within the normal range (Boyns et al., 1973; Franks et al., 1974; Kwa et al., 1974; Sheth et al., 1975) . Kirschner (1977) has pointed out that PRL levels in blood are quite labile and fluctuate greatly, thus making single determinations of this hormone of little value Thus the temporal response of serum PRL to TRH is very useful in the evaluation of pituitary PRL secretion in human subjects and the maximum increase in serum PRL above the base line level has been used as an index of response (Jacobs et al., 1973) . Mittra et al. (1944) reported that in their studies there were no statistical differences in the mean basal PRL levels between three groups (early breast cancer, advanced breast cancer and normal control). However, only women with advanced breast cancer exhibited a marginally greater pituitary reserve of PRL as evidenced by 
